Newborn screening (NBS) for rare conditions is performed in all 50 states in the USA. We have partnered with the California Department of Public Health Genetic Disease Laboratory to determine whether sufficient DNA can be extracted from archived dried blood spots (DBS) for nextgeneration sequencing in the hopes that next-generation sequencing can play a role in NBS. We optimized the DNA extraction and sequencing library preparation protocols for residual infant DBS archived over 20 years ago and successfully obtained acceptable whole exome and whole genome sequencing data. This sequencing study using DBS DNA without whole genome amplification prior to sequencing library preparation provides evidence that properly stored residual newborn DBS are a satisfactory source of DNA for genetic studies.
While DNA extracted from DBS has been successfully sequenced on next-generation sequencers in the past for WES and WGS, previous protocols required whole genome amplification (Hollegaard et al., 2013; Poulsen et al., 2016) . To test the hypothesis that properly stored DBSs, even ones archived decades ago, can yield DNA of sufficient quantity and quality for next-generation sequencing, we conducted three sets of studies to prepare DBS DNA for next-generation sequencing without whole genome amplification. In the first study, we established that acceptable WES data could be obtained without whole genome amplification, although the sequencing library had smaller than expected insert size. In the second study, we optimized the sequencing library preparation protocol to produce large insert size for WES sequencing. In the third study, we extended the protocol for WGS. Our finding shows that sufficient amounts of DNA can be extracted from old DBSs to produce acceptable WES and WGS data.
MATERIALS AND METHODS

DNA extraction
After completion of mandated state NBS, residual DBS on Grade 903 filter paper were archived (stacked together without any protective barriers) and stored desiccated at −20 • C. After obtaining a waiver of consent from the CDPH IRB for study of de-identified cases and controls, samples were located, brought to room temperature, and punched to remove two 3.2-mm discs, each corresponding to approximately 3 l of blood. The discs were deposited into wells of 96-well deep plates (Corning 3960; Corning, NY). A clean blank filter card was punched twice between each sample punch to minimize crosscontamination. Each plate included an internal positive control (punch from a DBS prepared from anonymous cord blood) and a negative punch from a blank filter card.
The DBS discs were digested in 200 l detergent solution with proteinase K (0.5 mg/ml) for 16 hr at 65 • C with 240 rpm shaking, after which the plates were spun at 370×g for 5 min. Genomic DNA was isolated using an AutoGenprep 965 robot (Autogen, Inc., Holliston, MA) with reagents supplied by the company. The standard tissue DNA extraction protocol was followed with an extra 70% ethanol pellet wash. Briefly, punches were incubated in 50 l RNA digestion solution and organic extraction with 180 l phenol/chloroform, with agitation followed by phase separation by centrifugation (4,000 rpm, 20 min).
The resulting aqueous phase, 390 L, was aspirated into fresh 96-well plates for DNA precipitation with 230 l isopropanol. After centrifugation, DNA pellets were washed twice with 450 l 70% ethanol. Pellets were air dried for 60 min and then hydrated overnight at RT in 50 l of 10% TE buffer. DNA from the duplicate punches was pooled to yield 100 l, of which 5 l was run on a 0.8% agarose TAE gel for 2 h. DNA size, integrity, and quantity were estimated by densitometry with a ChemiDoc Touch imaging system (Bio-Rad, Hercules, CA) using Image Lab software.
DNA shearing
DNA shearing was done on the Covaris S2 Sonicator (Woburn, MA) according to the manufacturer's instructions. All samples were sheared using the C1 program (intensity-5; duty cycle-10%; cycles per burst-200) at various treatment times to achieve optimal insert size. For insert size ∼250 bp, the treatment time of 90 sec (eight WES samples 01-02 to 01-09) or 120 sec (10 WGS samples M037, M068, M69, M75, M089, M097, M157, M179, U036, U040) was used. For insert size of ∼450 bp (four WES samples DB1a, DB1b, DB2a, and DB2b), the treatment time of 30 sec was used.
Sequencing library preparation
For WES and WGS library preparation, an average of 55 and 5 ng of input DNA were used, respectively. The sequencing libraries were made using the KAPA HTP or Hyper Library Preparation Kit according to manufacturer's instructions (Kapa Biosystems, Wilmington, MA).
For libraries optimized for larger inserts sizes, the ligation products were treated with the KAPA dual-SPRI size selection washing procedure. Samples DB1a and DB2a were subjected to the 0.4-0.6× wash, while DB2a and DB2b were subjected to the 0.5-0.7 × wash. 
Whole exome capture
DNA sequencing
WES sequencing for the initial eight samples (01-02 to 01-09) was performed on the HiSeq 2500 (Illumina, La Jolla, CA) with the paired-end 100 protocol, while the remaining four WES samples and the 10 WGS samples were sequenced on the HiSeq 4000, using the paired-end 150 protocol.
DNA sequencing QC analysis
Raw image files were analyzed and converted to base calls by real-time analysis using the default settings recommended by the manufacturer for data from the HiSeq 2500 or Hiseq 4000. Real-time analysis output base call files (*.bcl) were converted to FASTQ files with consensus assessment of sequence and variation (CASAVA pipeline, version 1.8, Illumina and version 2.17) using computer servers of the UCSF Institute for Human Genetics (IHG). CASAVA also de-multiplexed the data to obtain FASTQ files for individual samples. Initial sample and library quality control (QC) metrics produced from the Illumina SAV viewer .bin were evaluated using an in-house custom script which parses the were run through bcbio-nextgen on the BAM files to obtain information about uniquely mapped reads, % of duplicates, % of reads aligned to the target, mean target coverage, zero coverage regions, and mean insert sizes.
RESULTS
High-molecular-weight DNA was recovered from 100% of the samples.
DNA extraction yields from a representative selection of DBS were highly variable but normally distributed (Figure 1) , with mean recovery from 2 punches of 370 ng/ l (Range 150-920 ng/ l, SD 190 ng/ l).
The DNA samples extracted from DBS were used in three sets of pilot experiments. In the first experiment, we aimed to determine if old, archived, but properly stored DBS could yield DNA samples of sufficient quantity and quality for next-generation sequencing without whole genome amplification. Eight DNA samples extracted from DBS obtained in 1980 were sheared by sonication to produce DNA fragments ∼200 bp in length, according to the Covaris protocol; however, actual DNA length was observed to be only ∼150 bp. Shearing time was subsequently reduced to account for presumed single strand DNA nicking in the archived DBS, given the lack of evidence of degraded DNA in double strand DNA gels. The sheared DNA fragments were repaired, ligated to adaptors, and amplified to produce the sequencing library before incubation with whole exome capture probes to yield the WES library. The samples were sequenced in 4-plex (four samples per lane) on the Illumina HiSeq 2500 sequencer in high output mode using the paired-end 100 bp protocol. The results are shown in Table 1 (samples 01-02 to 01-09). The average coverage of the targeted bases was 69× (range 56-87×), with <0.01% of the target region not covered and 96.1% (range 95.3%-98.1%) of the target region with ≥10× coverage. This protocol has been used to generate WES data for ∼1,500 DBS DNA samples to be examined for gene mutations corresponding to their associated tandem mass spectrometry results for NBS metabolic disorders (unpublished data). The average coverage of target bases for the first 188 out of 1,500 samples sequenced was 60× with only 2.6% of the target bases not covered (data not shown).
Heterozygous variants are identified readily at this level of overall coverage.
In the second experiment, we aimed to produce longer DNA fragments to take advantage of the new paired-end 150 bp sequencing protocol offered on the HiSeq 4000 sequencer. Four DNA samples (DB1a, DB1b, DB2a, and DB2b), also extracted from DBS obtained in 1980, were sheared for an even shorter time of 30 sec to produce >400 bp fragments. After sample library preparation and exome capture, the samples were sequenced on the HiSeq 4000 sequencer (4-plex, pairedend 150 bp protocol). As shown in Table 1 , the average coverage of the targeted bases is 91× (range 74-114×), with <0.01% of the target region not covered and 97.2% (range 97.0%-97.4%) of the target region with ≥10× coverage. Alternative read fraction test was used to assess the degree of contamination found in the samples and no evidence of cross contamination was seen in the archival DBS-derived DNA.
In the third experiment, we explored the feasibility of WGS with DBS derived DNA samples. Ten residual DBS DNA samples (archived from 1996-2013) used in a WES study were sheared and prepared for WGS. Despite the low amount input DNA for shearing (∼5 ng), the resultant libraries were sequenced on the HiSeq 4000 sequencer (paired-end 150 bp protocol, one sample per lane) to evaluate the lower limit of input DNA for WGS. Because the insert size was ∼250 bp, and the starting DNA amounts were suboptimal, the mean exome target coverage was low (20×, range 11-28×). Nevertheless, 95.3% of the exome target region had ≥10× mean coverage for six of the samples that achieved ≥20× mean exome target coverage. The results are promising but far from perfect. We anticipate that with the protocol that yields sequencing libraries with larger inserts and sequencing to a higher depth (30× mean exome target coverage), the data quality will be more acceptable.
DISCUSSION
Dried blood spots stored in repositories around the world are potential resources for genetic and genomic analysis. This is to our knowledge the first study to use DBS DNA without whole genome amplification prior to WES and WGS sequencing library preparation. Based on these pilot study results, we have performed WES on a larger set of ∼1,500 DBS DNA samples. Analysis for concordance with metabolic screening in the CDPH NBS program is ongoing.
Our pilot study described here demonstrates that appropriately stored NBS DBS DNA is a good source of material for genomic studies in diverse populations. It is remarkable that no sign of cross contamination is detected even though the DBS cards are kept without any barriers between them. Among the 18 million DBS specimens in the California Biobank repository, there is substantial representation of many ethnic groups, as well as an increasing representation of individuals with backgrounds of mixed ethnicities. Although all of the disorders that are targets for NBS are rare, the ethnic distribution of disorders varies greatly (Feuchtbaum, Carter, Dowray, Currier, & Lorey, 2012) . Appropriate assessment of DNA variants in the context of NBS for rare disorders needs to be based on a deep understanding of the differences of variant frequencies in populations of different ethnicities. As an appropriate model, recent work on cystic fibrosis examined the fifty most common CFTR variants by ethnicity, and found that 20 of the most common variants in Hispanic CF patients were not shared with other ethnicities (Feuchtbaum et al., 2012) . This restriction of common variants to one ethnicity is reproduced in Asian and
African American populations as well (Schrijver et al., 2016) . The ability to produce high quality exome and genome sequences from newborn DBS, when achieved, offers an unparalleled opportunity to advance our understanding of rare disease associated and polymorphic variants in non-northern European populations, allowing for improved interpretation of DNA based screening and diagnosis in populations of diverse ancestry.
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